William RAOUL
  • E-mail :[email]
  • Phone : +33 2 47 36 62 67
  • Location : Tours, France
Last update 2017-09-01 16:27:21.193

William RAOUL PhD, CR1 INSERM, with HDR

Course and current status

Current position (GICC, Tours, France)

Since October 2013 : permanent researcher CR1, UMR 7292 (Tours, France). Fields : Therapeutic Monoclonal Antibodies, Oncology (Colorectal Cancer), Inflammatory Diseases (Rheumatology), Pharmacokinetics-Pharmacodynamics, Biomarkers, Quantitative Systems Pharmacology

Professional experience

2012-2013 : Researcher CR2, Inserm UMR S 968, Institut de la Vision (Paris, France). Fields : Age-related macular degeneration

2009-2012: Researcher CR2, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Inflammation, Chemokines

2006-2009 : Post-doctoral position, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Therapeutics


2017 : Habilitation à Diriger des Recherches (authorisation to supervise researches), University François Rabelais, Tours, France.

2005 : PhD in Life and Health Sciences (Toxicology) with honours, Inserm U651, University Paris XII, Créteil, France.

2001 : Master in Toxicology with honours, University Paris V Descartes, Paris, France.

Scientific summary

Research brief

The goal of the team is to understand how genetic and non-genetic variations translate into variable clinical responses to monoclonal antibodies in treated patients. Our general aim is to fill in the gap between genetics and clinical responses by establishing precise genotype-phenotype relationships for therapeutic antibody elimination and distribution (pharmacokinetics, PK) and mechanisms of action (pharmacodynamics, PD).


• Pharmacokinetic and pharmacokinetic-pharmacodynamic (PK-PD) modelling of therapeutic monoclonal antibodies in human and in preclinical studies.

• Pharmacogenetics and genotype-phenotype relationships of therapeutic antibodies. In vitro and ex vivo cellular models, clinical studies in treated patients.

• Analysis of role of Fc-gamma-receptors and of FcRn in elimination and distribution of antibodies (PK) and in concentration-effect relationships in vivo (PK-PD).

Image d’exemple